Abstract
Cefradine and co-trimoxazole pharmacokinetics were studied in a patient with peritonitis that complicated continuous ambulatory peritoneal dialysis (CAPD). Concentrations in the plasma reached after oral administration of 500 mg cefradine four times daily and 400/80 mg co-trimoxazole four times daily were for cefradine 100μg/ml, for trimethoprim 15μg/ml, and for sulfamethoxazole 100μ/ml, respectively. In the dialysate concentrations were reached of 35–70μ/ml cefradine, 2–5μ/ml trimethoprim and 8–17μg/ml sulfamethoxazole. The values for sulfamethoxazole are regarded too low to be clinically effective. Half-lives protein binding values and CAPD clearances are presented. Low CAPD clearances were obtained during the night and high values during the day. The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low. It seems questionable therefore whether co-trimoxazole can be used orally for the treatment of CAPD peritonitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levey A, Harrington J. Continuous peritoneal dialysis for chronic renal failure. Medicine 1982;61:330–9.
Golper T, Bennett W, Jones S. Peritonitis associated with chronic peritoneal dialysis. Dial Transplant 1978; 7:1173–8.
Rubin J, Rogers W, Taylor H, et al. Peritonitis during continuous ambulatory peritoneal dialysis. Ann Intern Med 1980;92:7–13.
Danziger LH. Controversies in antimicrobial therapy: innovative methods of administration. Am J Hosp Pharm 1986;43:646–52.
Knight KR, Polak A, Crump J, et al. Laboratory diagnosis and oral treatment of CAPD peritonitis. Lancet 1982;2:1301–4.
Boeschoten EW, Rietra PJ, Krediet RT, et al. CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 1985;16:789–97.
Drew PJT, Casewell MW, Desai N, et al. Cephalexin for the oral treatment of CAPD peritonitis. J Antimicrob Chemother 1984;13:153–9.
Searle M, Raman GV. Oral treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Clin Nephrol 1985;23:241–4.
Glasson P, Favre H. Treatment of peritonitis in continuous peritoneal dialysis patients with co-trimoxazole. Nephron 1984;36:65–7.
Singlas E, Rottembourg J, De Martin A, et al. Pharmacokinetics of co-trimoxazole using the peritoneal route: consequence for the treatment of peritonitis in patients maintained on peritoneal dialysis. In: Moncrief JW, Topovich RP, eds. CAPD update. New York: Masson, 1981:63–6.
Singlas E, Colin JN, Rottembourg J, et al. Pharmacokinetics of sulfamethoxazole-trimethoprim combination during chronic peritoneal dialysis: effects of peritonitis. Eur J Clin Pharmacol 1982;21:409–15.
Halstenson CE, Blevins RB, Salem NG, Matzje GR. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis. Clin Nephrol 1984;22:239–43.
Bratton AC, Marshall EK. New coupling component for sulfanilamide determination. J Biol Chem 1939; 128:537–50.
Vree TB, Hekster YA, Tijhuis MW. Metabolism of sulfonamides. Antibiot Chemother 1985;34:5–65.
Vree TB, Hekster YA, Damsma JE, Van der Kleijn E, O'Reilly WJ. Pharmacokinetics of N1-acetyl- and N4- acetylsulfamethoxazole in man. Clin Pharmacokinet 1979;4:310–9.
Clarke GS, Robinson ML. HPLC analysis of Cephradine in human serum and urine. J Clin Hosp Pharm 1983;8:373–4.
Janknegt R, Koks CHW. Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review. Pharm Weekbl [Sci] 1984;6:229–36.
Johnson CA, Welling PG, Zimmerman SW. Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients. Nephron 1984;38:57–61.
Vree TB, Hekster YA, Van Dalen R. Some consequences of drug choice and dosage regimen for patients with impaired kidney function. Drug Intell Clin Pharm 1983;17:267–73.
Vree TB, Hekster YA. Renal excretion of sulfonamides. Antibiot Chemother 1985;34:66–120.
Nouws JFM, Vree TB, Hekster YA.In vitro antimicrobial activity of hydroxy and N4-acetyl sulfonamide metabolites. Vet Quart 1985;7:70–2.
Van Dalen R, Vree TB, Baars AM, Termond EFS. Dosage adjustment for ceftazidime in patients with impaired kidney function. Eur J Clin Pharmacol 1986;30:597–605.
Hekster YA, Vree TB, Van Dalen R, Van der Kleijn E, Hafkenscheid J. Pharmacokinetics of cefuroxime and cefoxitin with normal, impaired and probenecid functionally impaired kidney function. In: Nelson JD, Grassi C, eds. Current Chemotherapy and Infectious Disease. Washington: American Society for Microbiology. 1980:570–3.
Vree TB, Martea M, Hekster YA, et al. Deterioration of human kidney function by high doses of co-trimoxazole in man. Pharm Weekbl [Sci] 1987:9:117–24.
Vree TB, Hekster YA, Hafkenscheid JCM, Van Dalen R, Friesen WT. The influence of the urine flow on renal clearance of creatinine in patients with normal and impaired kidney function. Drug Intell Clin Pharm 1981;15:194–8.
Hekster YA, Vree TB, Weemaes CMR, Rotteveel JJ. Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis. Pharm Weekbl [Sci] 1986;8:293–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martea, M., Hekster, Y.A., Vree, T.B. et al. Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis. Pharmaceutisch Weekblad Scientific Edition 9, 110–116 (1987). https://doi.org/10.1007/BF01960745
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01960745